Randomized clinical trials reporting the effect of statin use on cancer risk
| Study | Reference | Population | Duration | Statin | Results | |
|---|---|---|---|---|---|---|
| Name | Dose | |||||
| months | mg/day | |||||
| AVERT | Pitt et al. (1999) | 341 | 18 | Atorvastatin | 80 | Seven cases of cancer (three in atorvastatin-treated and four angioplasty-treated patients) |
| SCAT | Teo et al. (2000) | 460 | 48 | Simvastatin/enalapril | 28.5 | No significant differences in simvastatin/enalapril-treated-group and placebo group |
| ALLHAT-LLT | ALLHAT Officers (2002) | 10,355 | 97 | Pravastatin | 40 | No significant differences in pravastatin-treated and usual care for hypertension |
| TNT | LaRosa et al. (2005) | 10,001 | 57 | Atorvastatin | 10 or 80 | Cancer occurrence may not be associated with atorvastatin dose |
| IDEAL | Pedersen et al. (2005) | 8888 | 56 | Simvastatin Atorvastatin | 20 80 | No significant differences in simvastatin- and atorvastatin-treated groups |
| SPARCL | Amarenco et al. (2007) | 4731 | 57 | Atorvastatin | 80 | No significant differences in atorvastatin-treated and placebo group |
| LIPID | LIPID Study Group (1998) | 9014 | 73 | Pravastatin | 40 | No significant differences in pravastatin-treated and placebo group |
| AFCAPS | Downs et al. (1998) | 6605 | 62 | Lovastatin | 20–40 | No significant differences in treated and placebo groups |
| HPS | Heart Protection Study Collaborative Group (2002) | 20,536 | 60 | Simvastatin | 40 | No significant differences in simvastatin-treated and placebo group |
| 4S | Strandberg et al. (2004) | 4444 | 120 | Simvastatin | 20 or 40 | No significant differences in simvastatin-treated and placebo group |
| PROSPER | Shepherd et al. (2002) | 5804 | 38 | Pravastatin | 40 | Significant increase of cancer incidence in pravastatin-treated and placebo group especially breast cancer |
| CARE | Sacks et al. (1996) | 4159 | 60 | Pravastatin | 40 | Significant increase in breast cancer in postmenopausal women treated with pravastatin compared with placebo. No significant reduction of colon cancer incidence and no decrease in the new diagnosed melanoma |
| WOSCOPS | Shepherd et al. (1995) | 6595 | 57 | Pravastatin | 40 | Significant increase of overall cancers in treated and placebo group |
| WOSCOPS | Ford et al. (2007) | Survivors of previous trials [Shepherd et al. (1995)] | 120 | Pravastatin | 40 | No significant increased risk in pravastatin treated and placebo group |